The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Blastomycosis Treatment Market During The Forecast Period 2026–2030?
The blastomycosis treatment market has experienced robust growth in recent years. Projections indicate its expansion from $0.73 billion in 2025 to $0.79 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.6%. This historical increase can be ascribed to several factors, including enhanced awareness of systemic fungal infections, the accessibility of antifungal drug therapies, the growth of diagnostic laboratory services, greater clinical identification of blastomycosis cases, and the development of infectious disease treatment programs.
The blastomycosis treatment market size is poised for robust expansion in the coming years, with projections indicating it will reach $1.07 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.9%. This anticipated growth can be attributed to several factors including an increased emphasis on early and precise diagnosis, the ongoing advancement of improved antifungal formulations, the expansion of specialized infectious disease care centers, the rising adoption of personalized treatment approaches, and escalating investment in fungal disease research. Prominent trends expected during this period encompass the growing embrace of advanced diagnostic protocols, an increase in the use of targeted antifungal therapies, the broadening scope of therapeutic drug monitoring practices, a heightened focus on early disease detection, and enhanced integration of clinical decision support tools.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33044&type=smp
Which Major Factors Are Driving The Expansion Of The Blastomycosis Treatment Market?
An anticipated rise in the prevalence of fungal diseases is projected to stimulate expansion in the blastomycosis treatment market in the coming years. These are infections stemming from pathogenic fungi, capable of entering the body via inhalation, direct contact, or environmental exposure. This increase is largely fueled by climate-linked environmental shifts, where heightened precipitation and flooding foster damp, organic soil environments conducive to fungal spore proliferation and subsequent human contact. The expanding presence of fungal infections boosts the need for effective treatment methods, given that prompt diagnosis and appropriate antifungal treatment are crucial for averting serious complications and lowering fatality rates. For example, the UK Health Security Agency, a government body based in the UK, reported in May 2025 that bloodstream infections caused by yeast saw a 4% rise in 2024 compared to 2023, escalating from 2,170 to 2,247 documented cases. Consequently, the escalating incidence of fungal diseases is propelling the growth of the blastomycosis treatment market. The expanding population of immunocompromised individuals is anticipated to drive the future growth of the blastomycosis treatment market. This demographic consists of people with compromised immune systems, resulting from existing illnesses, genetic factors, or medical interventions like chemotherapy, immunosuppressive medications, or organ transplants. This group is growing because of enhanced survival rates among those with chronic conditions, coupled with the broader application of immunosuppressive and immunomodulating treatments for autoimmune and inflammatory ailments. Blastomycosis treatment assists the immunocompromised by delivering potent antifungal therapy, which manages severe and widespread infections, diminishes fungal load, and wards off life-threatening complications in patients with compromised immune defenses. For example, a South Korea-based journal, Infection & Chemotherapy (IC), stated in September 2024 that by December 2023, South Korea had recorded a total of 19,001 HIV diagnoses, with 1,219 (6.4%) being women. In 2022 alone, 1,066 new HIV cases were discovered, among them 82 women (7.7%), consisting of 35 Korean nationals and 47 foreign nationals. In that same year, the overall count of Korean nationals living with HIV in the country amounted to 15,880, with women making up 998 of those cases. Consequently, the expanding immunocompromised population is stimulating the growth of the blastomycosis treatment market.
What Market Segments Are Evaluated Within The Blastomycosis Treatment Market?
The blastomycosis treatment market covered in this report is segmented –
1) By Treatment Type: Antifungal Drugs; Surgical Intervention
2) By Anatomy: Lung; Bones; Central Nervous System; Other Anatomy
3) By Dosage: Tablet; Injection; Capsule; Other Dosage forms
4) By Route Of Administration: Intravenous; Oral; Other Route Of Administrations
5) By End-User: Hospitals; Outpatient Clinics; Diagnostic Laboratories
Subsegments:
1) By Antifungal Drugs: Azole Antifungal Agents; Polyene Antifungal Agents; Echinocandin Antifungal Agents; Oral Antifungal Formulations; Intravenous Antifungal Formulations
2) By Surgical Intervention: Lesion Debridement Procedures; Abscess Drainage Procedures; Lung Resection Procedures; Soft Tissue Excision Procedures
What Industry Trends Are Redefining The Blastomycosis Treatment Market?
Major companies active in the blastomycosis treatment market are prioritizing the development of sophisticated solutions, including antifungal drug development, to achieve better treatment efficacy, improved safety profiles, and a more robust capacity to address unmet needs for severe systemic fungal infections. Antifungal drug development focuses on creating antifungal therapies designed to enhance current treatments by increasing effectiveness, decreasing toxicity, overcoming drug resistance, and offering superior dosing, formulation, or delivery methods. For example, in June 2024, Elion Therapeutics, a US-based biotechnology company, declared that Elion Therapeutics’ SF001 is a next-generation polyene antifungal and a new analog of amphotericin B, a drug long established as a primary treatment for severe systemic fungal infections, including blastomycosis. Although the press release specifically mentioned invasive fungal infections such as aspergillosis, the mechanism of action of SF001 as an amphotericin B derivative, engineered to retain broad-spectrum antifungal activity while reducing toxicity, also makes it relevant for the treatment of blastomycosis. In essence, because amphotericin B is effective against Blastomyces dermatitidis, a drug built on its structure and function, like SF001, is logically connected to blastomycosis therapy.
Who Are The Top Market Participants Influencing The Blastomycosis Treatment Market?
Major companies operating in the blastomycosis treatment market are Johnson & Johnson, Pfizer Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Astellas Pharma Inc., bioMérieux SA, Cipla Ltd., Lupin Limited, SCYNEXIS Inc., and F2G Ltd.
Read the full blastomycosis treatment market report here:
https://www.thebusinessresearchcompany.com/report/blastomycosis-treatment-market-report
Which Region Is Projected To Lead The Blastomycosis Treatment Market During The Forecast Period?
North America was the largest region in the blastomycosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blastomycosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Blastomycosis Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33044&type=smp
Browse Through More Reports Similar to the Global Blastomycosis Treatment Market 2026, By The Business Research Company
Mycosis Fungoides Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/mycosis-fungoides-treatment-global-market-report
Onychomycosis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report
Onychomycosis Market Report 2026
https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model